BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095

Reuters12-04

BRIEF-Pliant <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Interim Data From PLN-101095

Dec 4 (Reuters) - Pliant Therapeutics Inc PLRX.O:

PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS
PLIANT THERAPEUTICS INC: TO ACCELERATE DEVELOPMENT OF PLN-101095 WITH INITIATION OF A PHASE 1B EXPANSION TRIAL IN 2026

Source text: ID:nGNX1plmDL

Further company coverage: PLRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588488146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588488146","market":"us","top_or_hot":-1,"title":"BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Interim Data From PLN-101095</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Pliant Therapeutics Inc <span>PLRX.O</span>:</p><ul><li><p>PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS</p></li><li><p>PLIANT THERAPEUTICS INC: TO ACCELERATE DEVELOPMENT OF PLN-101095 WITH INITIATION OF A PHASE 1B EXPANSION TRIAL IN 2026</p></li></ul><p>Source text: <span>ID:nGNX1plmDL</span></p><p>Further company coverage: <span>PLRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Interim Data From PLN-101095</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Pliant Therapeutics Inc <span>PLRX.O</span>:</p><ul><li><p>PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS</p></li><li><p>PLIANT THERAPEUTICS INC: TO ACCELERATE DEVELOPMENT OF PLN-101095 WITH INITIATION OF A PHASE 1B EXPANSION TRIAL IN 2026</p></li></ul><p>Source text: <span>ID:nGNX1plmDL</span></p><p>Further company coverage: <span>PLRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRX","symbol_name":"Pliant Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02B:1","article_id":"2588488146","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588488146","pubTimestamp":1764851965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095Dec 4 (Reuters) - Pliant Therapeutics Inc PLRX.O:PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHEC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRX":"Pliant Therapeutics, Inc.","BK4007":"制药"},"translate_title":"BRIEF-Pliant Therapeutics公布PLN-101095的中期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRX":0.9},"content_text":"BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095Dec 4 (Reuters) - Pliant Therapeutics Inc PLRX.O:PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORSPLIANT THERAPEUTICS INC: TO ACCELERATE DEVELOPMENT OF PLN-101095 WITH INITIATION OF A PHASE 1B EXPANSION TRIAL IN 2026Source text: ID:nGNX1plmDLFurther company coverage: PLRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588488146","isCrawlerRequest":true}